

# Index

## A

Acalabrutinib, 123  
Activated PI3K/AKT signaling, 65  
Activation of protein kinase B (AKT), 40  
Acute lymphoblastic leukemia (ALL), 2, 42  
Adenosine production, 176  
Afucosylation, 38  
Anaplastic large cell lymphoma (ALCL), 41, 62  
Anti-apoptotic family members, 4  
Antibody-dependent cellular cytotoxicity (ADCC), 31–33, 38, 40, 42, 61  
Antibody-dependent phagocytic cytotoxicity (ADCP), 31, 32  
Antibody-drug conjugates (ADC), 40, 41  
  antigen-related resistance, 63  
  apoptosis, 65  
  defects in internalization and lysosomal function, 64  
  drug efflux pumps, 65  
  first-generation, 58  
  HL, 58  
  immune therapy agents, 58  
  lymphoma  
    brentuximab vedotin (Bv), 62  
    CD33-positive AML, 62  
    development, 63  
    gemtuzumab ozogamicin, 61  
    IO, 62, 63  
  mechanisms of resistance  
    apoptotic regulation, 66  
    drug efflux pumps, 66  
    loss of cell surface antigen, 65  
    response rate (RR), 65  
  NHL, 58  
  optimization, 66, 67

  plasma membrane, 63, 64  
  signaling pathways, 65  
  structure and components  
    critical factors, 59, 60  
    cytotoxic agents, 61  
    linker design, 61  
    selection of mAbs, 60, 61  
    tumor tissue, 60

Anti-CD19 agents, 63  
Anti-CD19 CAR-T cell products (CAR19)  
  B-cell lymphoma trials, 194, 196  
  in lymphoma, 196, 197  
Anti-CD20 monoclonal antibody therapy, 34  
Anti-CD79b-vc-MMAE ADC, 66  
Antigen-antibody (Ag-Ab) complexes, 61  
Anti-microtubule compounds, 61  
Apoptosis, 4, 6, 8–10, 13–16  
Auristatin analogs, 61  
Autophagy process, 98

## B

B acute lymphoblastic leukemia (B-ALL), 6, 8, 10–12, 14–16, 183, 184  
BCB-3111, 124  
B-cell lymphoma-2 (BCL-2), 131  
B-cell non-Hodgkin lymphoma (B-NHL), 28–30  
B-cell receptor (BCR) signaling  
  antigen-binding immunoglobulin, 114, 115  
  types of, 114  
BCL2 rheostat, 3, 4  
BCL-XL, 66  
Belinostat, pan-HDACi, 95  
Bendamustine, 38

- Berlin-Frankfurt-Munster (BFM) protocols, 2  
 $\beta$ -2-Microglobulin ( $\beta$ 2M) mutations, 174  
 Bispecific antibodies  
   extramedullary sites, 185, 186  
   loss of target antigen, 186, 187  
   novel therapeutic constructs, 182  
   resistance mechanisms, 185  
 Bispecific T-cell engagers (BiTEs), 42  
   AFM11, 184  
   bispecific antibodies, 182  
   blinatumomab, 182–184  
   CD30, 184  
   patients with NHL, 185  
   resistance mechanisms, 185  
   suboptimal T-cell response, 187–189  
 Blinatumomab, 42, 182–184  
 Bortezomib, 76, 77, 79  
 Brentuximab vedotin (Bv), 40, 41, 62  
 Bruton's tyrosine kinase (BTK)  
   B-cell lymphoma-2 (BCL-2) family  
     members mediated resistance, 131  
   canonical and non-canonical NF- $\kappa$ B  
     signaling pathways, 130  
   cell cycle deregulation, 132  
   chromosomal abnormality, 129, 130 (*see also*  
     *Combine BTK inhibitors*)  
   hepatocellular carcinoma (Tec) family, 116  
   ibrutinib (*see* Ibrutinib)  
   kinase inhibitors, 134  
   mutational resistance, 126, 127, 129  
   mutations, 116  
   non-covalent inhibitors, 133, 134  
   normal B-cell development, 116  
   PI3K-AKT/mTOR pathway, 130, 131  
   primary and secondary resistance, 124  
   putative domains, 116  
   reported mechanisms, 125, 126 (*see also*  
     Second generation inhibitors)  
   TME mediated resistance, 132  
 Burkitt lymphoma, 16
- C**  
 Calicheamicin analogs, 61  
 Cancer therapy, 156  
 Canonical and non-canonical NF- $\kappa$ B signaling  
   pathways, 130  
 Carfilzomib, 77  
 Caspase-independent cell death, 40  
 Caspase recruitment domain family member  
   11 (CARD11), 115  
 CCRF-CEM cells, 5  
 CD19 alternative splicing, 199  
 CD19 "masking", 200, 201  
 CD19 mutation, 199  
 CD20, 34  
 CD33-positive AML, 62  
 CD73 expression, 176  
 Cell cycle deregulation, 132  
 Cell signaling-related mechanisms, 97, 98  
 Cell surface antigen, 65  
 Chaperone proteins, 7  
 Checkpoint blockade inhibitors  
   CTLA-4, 162–164  
     PD-1 expression, 164–167  
     PD-L1 expression, 167, 169  
     refractory/relapsed cancers, 169  
 Chemosensitization, 32, 40  
 Chemotherapies, 29, 65  
 Chemotherapy sensitization, 100  
 Children's Oncology Group (COG) trials, 62  
 Chimeric antigen receptor (CAR) T-cells  
   CD19 "masking", 200, 201  
   immune scape, antigen loss, 198, 199  
   myeloid switch, 199  
   novel target antigens, 196  
   principle and clinical trial overview,  
     194–195  
   senescence and exhaustion, 200  
 Chromatin accessibility, 8  
 Chromatin immunoprecipitation with  
   sequencing (ChIP-seq), 4  
 Chronic lymphocytic leukemia (CLL), 7,  
   36–39  
 Circulating CD20 (cCD20) antigens, 39  
 Coltuximab ravtansine, 63  
 Combine BTK inhibitors  
   BCL-2 inhibitors, 138  
   cellular process, 139, 140  
   immunotherapies, 139  
   oncogenic, 134, 137, 138  
 Complement dependent cytotoxicity (CDC),  
   31, 32, 35–37  
 Complete response (CR), 62  
 CTLA-4 expression, 162–164  
 Cyclic adenosine monophosphate (cAMP)  
   signaling, 9  
 Cytotoxic agents, 60, 61, 65
- D**  
 Delanzomib, 78  
 Denintuzumab mafotin, 63  
 Dexamethasone (DEX), 9  
 Diffuse large B cell lymphoma (DLBCL), 9,  
   29, 62, 80, 81  
 DNA binding domain (DBD), 4  
 DNA damage and repair mechanisms, 96

Drug efflux mechanisms, 97  
Drug efflux pumps, 65, 66  
Drug resistance, 15  
Drug-to-antibody ratios, 66, 67

## E

Effective linker designs, 66  
Endocytosis, 64  
Endoplasmic reticulum (ER) stress signaling, 98  
Entinostat, 95  
Epigenetic regulation, 35  
Epigenetic therapy, 100  
ERK signaling, 10  
*ETV6/RUNX1* fusion oncogene, 6  
Event-free survival (EFS) rates, 2  
Extracellular signal related kinase 1 and 2 (ERK1/2), 32

## F

Fc $\gamma$  receptors (Fc $\gamma$ R), 37–39  
Follicular lymphoma, 16, 66

## G

GC receptor (GR)  
  chaperone proteins, 3  
  endogenous/exogenous GC ligand, 3  
  extrinsic mechanisms  
    epigenetic regulation, 8  
    metabolism, 13–15  
    miRNAs (*see* MicroRNAs (miRNAs))  
    signal transduction (*see* Signal transduction)  
  GREs, 3  
  intrinsic mechanisms  
    autoinduction, 6  
    expression and function, 6, 7  
    *NR3C1* mutations, 4, 5  
GC response elements (GREs), 3  
Gemtuzumab ozogamicin (GO) resistance, 61, 65  
Glucocorticoids (GC)  
  action mechanism, 3, 4  
  ALL-BFM protocols, 2  
  anti-apoptotic family members, 4  
  BCL2 rheostat, 3, 4  
  ChIP-seq, 4  
  EFS rates, 2  
  GR (*see* GC receptor (GR))  
  intrinsic apoptotic pathway, 4

resistance

  GR (*see* GC receptor (GR))

Glucose metabolism, 14  
Glutathione *S*-transferases (GSTs), 14  
Granulocyte-macrophage colony stimulating factor (GM-CSF), 35  
GR $\alpha$  sensitivity, 7  
GR $\beta$ /GR $\alpha$  ratio, 7  
GR $\beta$  isoform, 7  
GR $\gamma$  isoform, 7

## H

HDAC inhibitors (HDACi)  
  autophagy process, 98  
  belinostat, pan-HDACi, 95  
  cell cycle arrest, 92  
  cell death, 92  
  cell signaling-related mechanisms, 97, 98  
  chemotherapy sensitization, 100  
  classification, 92  
  deacetylation activity, 92  
  DNA damage and repair mechanisms, 96  
  drug efflux mechanisms, 97  
  entinostat, 95  
  epigenetic therapy, 100  
  ER stress signaling, 98  
  immunotherapy, 101  
  mocetinostat, 95  
  panobinostat, 94  
  reactive oxidative species, 96  
  redox pathway, 96  
  romidepsin (depsipeptide), 94  
  targeted molecular therapies, 88  
  toxicity, 101  
  vorinostat (suberoylanilide hydroxamic acid), 92  
Histone deacetylase (HDAC), 8  
  acquired resistance, 99  
  classification, 91  
  enzyme expression, lymphoma, 99  
  epigenetic modification, 88  
  HDACi (*see* HDAC inhibitors (HDACi))  
  hypoacetylation, 91  
  lysines modification, histone tails, 90  
  NHL lymphoma, 88, 89  
  non-histone proteins, 91  
  in reactive lymph nodes, 91  
Hodgkin lymphoma (HL), 39, 41, 42, 58  
HSP70 system, 7  
HSP90 system, 7  
Human anti rituximab (HACA) antibodies, 30  
11 $\beta$ -Hydroxysteroid dehydrogenase (HSD), 13, 14

**I**

- Ibritumomab tiuxetan, 40
- Ibrutinib
  - description, 117
  - efficacy and tolerability, 117
  - phase 2 and 3 clinical trials, 117–119
  - phase 3 RESONATE-2 study, 121
  - preclinical studies, 117
  - primary FL cells, 120
  - single-agent, 117
  - temsirolimus, 121
  - TLR and NF- $\kappa$ B pathways, 120
- Immunotherapy, 29, 101
- Innate anti-PD-1 resistance (IPRES)
  - signatures, 173
- Inotuzumab ozogamicin (IO), 62, 63
- Interferon gamma (IFN- $\gamma$ ), 35
- $^{131}$ I-tositumomab, 40, 41
- Ixazomib, 78

**J**

- JAK/STAT signaling, 12
- Janus kinase 1 (JAK1) mutation, 175
- Janus kinase 2 (JAK2) mutation, 175
- Jurkat cells, 5

**L**

- Large B-cell lymphoma, 196
- Leukemia
  - ALL, 2
  - CLL, 7
- Ligand binding domain (LBD), 4, 5
- Linker design, 61
- Lipid metabolism, 15
- Loncastuximab tesirine, 63
- Lymphoma
  - ADC (*see* Antibody-drug conjugates (ADC))
    - ALCL, 62
    - B cell, 63
    - Burkitt, 16
    - DLBCL, 9, 62
    - follicular, 16, 66
    - NHL, 8, 58

**M**

- Mantle cell lymphoma (MCL), 79
- Marizomib, 78
- MDR1 drug exporter expression, 66
- Membrane spanning 4-domains A1 (MS4A1)
  - gene, 35

**Metabolism, GR**

- ALL cell lines, 14
- CEM-C7 cells, 15
- ChIP-seq, 15
- culturing cells, 14
- GC ligand, 13
- GC sensitivity and resistance, 14
- genetic silencing of MCL1, 15
- glucose metabolism, 14
- GSTs, 14
- HSD, 13, 14
- lipid, 15
- 2-DG, 14
- MicroRNAs (miRNAs)
  - dysfunctional expression, 16
  - microarray analysis, 16
  - miR-100/99a, 16
  - miR-124, 16
  - miR-128b, 17
  - miR-142-3p, 17
  - miR-17, 16
  - miR-182, 17
  - miR-185-5p, 17
  - miR-221, 17
  - non-coding RNAs, 15
  - 3'UTR, 15
- Minimal residual disease (MRD), 6
- Mitogen activated protein kinase (MAPK)
  - signaling, 9, 10, 32
- Mocetinostat, 95
- Monoclonal antibody
  - B-NHL, 28–30
  - mechanisms of activity
    - ADCC/ADCP, 31, 32
    - anti-CD20 antibody, 31
    - caspase-dependent apoptosis, 32
    - CDC, 31
    - cellular function, 32
    - chemosensitization, 32
    - disease- and antibody-dependent, 33
    - induction of cell death, 32
    - intracellular signaling effects, 32
    - PCD, 31, 32, 40
    - rituximab, 31
    - vaccination effect, 32
  - mechanisms of resistance
    - ADCs, 40, 41
    - ALL, 42
    - antigen expression, 41
    - antigenic alterations, 33–35
    - apoptosis, 39, 40
    - bi-specific antibodies, 42
    - blinatumomab, 42
    - brentuximab vedotin (Bv), 40, 41

circulating antigen, 39  
 complement mediated resistance, 36, 37  
 Fc $\gamma$ R, 37–39  
 MMAE, 40, 41  
 RICs, 40  
 target cell apoptosis, 41  
 principle, 28  
 rituximab, 28–30  
 toxins/radiotherapeutic agents, 29  
 Monomethyl auristatin E (MMAE), 40, 41, 62  
 Multi-agent chemotherapy, 58  
 Mycosis fungoides (MF), 62  
 Myeloid switch, 199

## N

NALP3 inflammasome, 6  
 Natural killer (NK) cells, 31  
 Navitoclax, 66  
 Nicotinamide adenine dinucleotide phosphate (NADPH), 40  
 Non-Hodgkin lymphoma (NHL), 8, 58  
   clinical trials, B-cell, 79  
   DLBCL, 80, 81  
   MCL, 79  
   PMBCL, 81  
   T-LL therapy, 81  
 NOTCH signaling, 12, 13  
*NR3C1* mutations, 4, 5  
 N-terminal transactivation domain (NTD), 4  
 Nuclear factor kappa B (NF- $\kappa$ B) signaling pathways, 32  
 Nuclear receptor corepressor (NCoR) complex, 8

## O

Obinutuzumab, 34, 38–40  
 Objective response (OR), 62  
 Ofatumumab, 36, 38  
 Oncogenic inhibitors, 134, 137, 138  
 Oprozomib, 78

## P

Panobinostat, 94  
 PD-1 expression, 164–167  
 PD-L1 expression, 167, 169  
 Pediatrics, 58  
 Phosphodiesterases (PDEs), 9  
 Phospholipase C gamma 2 (PLC $\gamma$ 2), 32  
 PI3K/AKT/mTOR pathway, 10–12, 130, 131  
 Pinatuzumab vedotin, 63  
 Polymorphisms, 36, 37

Prednisone good response (PGR), 2  
 Prednisone poor response (PPR), 2  
 Primary cutaneous ALCL (pcALCL), 62  
 Primary mediastinal large B-cell lymphoma (PMBCL), 81  
 Pro- and anti-apoptotic regulators, 39  
 Programmed cell death (PCD), 31, 32, 40  
 Progression-free survival (PFS) rates, 62  
 Proteasome inhibitor therapy  
   plasma cell cancer, 72  
   therapy resistance, 81, 82 (*see also*  
   Ubiquitin proteasome system)

## R

Radioimmunoconjugates (RICs), 40  
 R-CHOP regimen, 29  
 Reactive oxygen species (ROS), 40, 96  
 Redox pathway, 96  
 Relapsed/refractory (R/R) B-cell lymphoma, 114  
 Resistance  
   ADC (*see* Antibody-drug conjugates (ADC))  
   GC (*see* Glucocorticoids (GC))  
   monoclonal antibody (*see* Monoclonal antibody)  
 Rituximab, 28–31  
 Rituximab-resistant B-NHL cell, 34  
 Romidepsin (depsipeptide), 94

## S

Second generation inhibitors  
   acalabrutinib, 123  
   BCB-3111, 124  
   tirabrutinib, 123  
 Shaving effect, 34  
 Signal transducer and activator of transcription 3 (STAT3), 32  
 Signal transduction  
   cAMP, 9  
   JAK/STAT, 12  
   lymphoid malignancies, 8  
   MAPK, 9, 10  
   NOTCH, 12, 13  
   PI3K/AKT/mTOR, 10–12  
   Src family kinase signaling, 13  
 Spleen-associated tyrosine kinase (SYK), 40  
 Src family kinase signaling, 13

## T

T-cell exhaustion, 171  
 T-cell lymphocytes  
   activation, 158

T-cell lymphocytes (*cont.*)  
 inhibition, 159  
 maturation process, 157  
 TCR, 158  
 T-cell maturation process, 157  
 T-cell receptor (TCR), 158  
 3' Untranslated region (3'UTR), 15  
 Tirabrutinib, 123  
 T-lymphoblastic lymphoma (T-LL) therapy, 81  
 Tositumomab, 40  
 Trichostatin A, 35  
 Tumor cells, 36  
 Tumor immunogenicity, 174  
 Tumor infiltrating T-cells, 170  
 Tumor microenvironment (TME), 132  
   development and progression, 156  
   immune cells, 157  
   Treg cells, 157  
 Tumor necrosis factor alpha  
   (TNF- $\alpha$ ), 35  
 2-Deoxy-D-glucose (2-DG), 14  
 Type I rituximab antibody, 34  
 Type II anti-CD20 monoclonal antibodies, 40  
 Type II tositumomab-like antibody, 34

**U**

Ubiquitin-activating enzymes, 74  
 Ubiquitin proteasome system  
   bortezomib, 76, 77  
   carluzomib, 77  
   core 20S proteasome particle, 75  
   E4, 75  
   eukaryotic cells, 73  
   ixazomib and delanzomib, 78  
   marizomib, 78  
   Nrf1 protein, 76  
   oprozomib, 78  
   p97 assisted retro-translocation pathway, 76  
   selective immunoproteasome inhibitors, 75  
   targeted proteolysis, 75  
   26S proteasome, 73  
   ubiquitination, 74  
 Ubiquitination, 74  
 Ubiquitin-conjugating enzymes, 74

**V**

Vaccination effect, 32  
 Vorinostat (suberoylanilide hydroxamic acid), 92